Cargando…

Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis

The burden of influenza is disproportionally higher among older adults. We evaluated the relative vaccine effectiveness (rVE) of adjuvanted trivalent (aIIV3) compared to high-dose trivalent influenza vaccine (HD-IIV3e) against influenza and cardio-respiratory disease (CRD)-related hospitalizations/E...

Descripción completa

Detalles Bibliográficos
Autores principales: Levin, Myron J., Divino, Victoria, Shah, Drishti, DeKoven, Mitch, Mould-Quevedo, Joaquin, Pelton, Stephen I., Postma, Maarten J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540032/
https://www.ncbi.nlm.nih.gov/pubmed/34696254
http://dx.doi.org/10.3390/vaccines9101146
_version_ 1784588889550225408
author Levin, Myron J.
Divino, Victoria
Shah, Drishti
DeKoven, Mitch
Mould-Quevedo, Joaquin
Pelton, Stephen I.
Postma, Maarten J.
author_facet Levin, Myron J.
Divino, Victoria
Shah, Drishti
DeKoven, Mitch
Mould-Quevedo, Joaquin
Pelton, Stephen I.
Postma, Maarten J.
author_sort Levin, Myron J.
collection PubMed
description The burden of influenza is disproportionally higher among older adults. We evaluated the relative vaccine effectiveness (rVE) of adjuvanted trivalent (aIIV3) compared to high-dose trivalent influenza vaccine (HD-IIV3e) against influenza and cardio-respiratory disease (CRD)-related hospitalizations/ER visits among adults ≥65 years during the 2019–2020 influenza season. Economic outcomes were also compared. A retrospective cohort analysis was conducted using prescription, professional fee claims, and hospital data. Inverse probability of treatment weighting (IPTW) was used to adjust for confounding. IPTW-adjusted Poisson regression was used to evaluate the adjusted rVE of aIIV3 versus HD-IIV3e. All-cause and influenza-related healthcare resource utilization (HCRU) and costs were examined post-IPTW. Recycled predictions from generalized linear models were used to estimate adjusted costs. Adjusted analysis showed that aIIV3 (n = 798,987) was similarly effective compared to HD-IIV3e (n = 1,655,979) in preventing influenza-related hospitalizations/ER visits (rVE 3.1%; 95% CI: −2.8%; 8.6%), hospitalizations due to any cause (−0.7%; 95% CI: −1.6%; 0.3%), and any CRD-related hospitalization/ER visit (0.9%; 95% CI: 0.01%; 1.7%). Adjusted HCRU and annualized costs were also statistically insignificant between the two cohorts. The adjusted clinical and economic outcomes evaluated in this study were comparable between aIIV3 and HD-IIV3e during the 2019–2020 influenza season.
format Online
Article
Text
id pubmed-8540032
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85400322021-10-24 Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis Levin, Myron J. Divino, Victoria Shah, Drishti DeKoven, Mitch Mould-Quevedo, Joaquin Pelton, Stephen I. Postma, Maarten J. Vaccines (Basel) Article The burden of influenza is disproportionally higher among older adults. We evaluated the relative vaccine effectiveness (rVE) of adjuvanted trivalent (aIIV3) compared to high-dose trivalent influenza vaccine (HD-IIV3e) against influenza and cardio-respiratory disease (CRD)-related hospitalizations/ER visits among adults ≥65 years during the 2019–2020 influenza season. Economic outcomes were also compared. A retrospective cohort analysis was conducted using prescription, professional fee claims, and hospital data. Inverse probability of treatment weighting (IPTW) was used to adjust for confounding. IPTW-adjusted Poisson regression was used to evaluate the adjusted rVE of aIIV3 versus HD-IIV3e. All-cause and influenza-related healthcare resource utilization (HCRU) and costs were examined post-IPTW. Recycled predictions from generalized linear models were used to estimate adjusted costs. Adjusted analysis showed that aIIV3 (n = 798,987) was similarly effective compared to HD-IIV3e (n = 1,655,979) in preventing influenza-related hospitalizations/ER visits (rVE 3.1%; 95% CI: −2.8%; 8.6%), hospitalizations due to any cause (−0.7%; 95% CI: −1.6%; 0.3%), and any CRD-related hospitalization/ER visit (0.9%; 95% CI: 0.01%; 1.7%). Adjusted HCRU and annualized costs were also statistically insignificant between the two cohorts. The adjusted clinical and economic outcomes evaluated in this study were comparable between aIIV3 and HD-IIV3e during the 2019–2020 influenza season. MDPI 2021-10-08 /pmc/articles/PMC8540032/ /pubmed/34696254 http://dx.doi.org/10.3390/vaccines9101146 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Levin, Myron J.
Divino, Victoria
Shah, Drishti
DeKoven, Mitch
Mould-Quevedo, Joaquin
Pelton, Stephen I.
Postma, Maarten J.
Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis
title Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis
title_full Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis
title_fullStr Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis
title_full_unstemmed Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis
title_short Comparing the Clinical and Economic Outcomes Associated with Adjuvanted versus High-Dose Trivalent Influenza Vaccine among Adults Aged ≥ 65 Years in the US during the 2019–20 Influenza Season—A Retrospective Cohort Analysis
title_sort comparing the clinical and economic outcomes associated with adjuvanted versus high-dose trivalent influenza vaccine among adults aged ≥ 65 years in the us during the 2019–20 influenza season—a retrospective cohort analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540032/
https://www.ncbi.nlm.nih.gov/pubmed/34696254
http://dx.doi.org/10.3390/vaccines9101146
work_keys_str_mv AT levinmyronj comparingtheclinicalandeconomicoutcomesassociatedwithadjuvantedversushighdosetrivalentinfluenzavaccineamongadultsaged65yearsintheusduringthe201920influenzaseasonaretrospectivecohortanalysis
AT divinovictoria comparingtheclinicalandeconomicoutcomesassociatedwithadjuvantedversushighdosetrivalentinfluenzavaccineamongadultsaged65yearsintheusduringthe201920influenzaseasonaretrospectivecohortanalysis
AT shahdrishti comparingtheclinicalandeconomicoutcomesassociatedwithadjuvantedversushighdosetrivalentinfluenzavaccineamongadultsaged65yearsintheusduringthe201920influenzaseasonaretrospectivecohortanalysis
AT dekovenmitch comparingtheclinicalandeconomicoutcomesassociatedwithadjuvantedversushighdosetrivalentinfluenzavaccineamongadultsaged65yearsintheusduringthe201920influenzaseasonaretrospectivecohortanalysis
AT mouldquevedojoaquin comparingtheclinicalandeconomicoutcomesassociatedwithadjuvantedversushighdosetrivalentinfluenzavaccineamongadultsaged65yearsintheusduringthe201920influenzaseasonaretrospectivecohortanalysis
AT peltonstepheni comparingtheclinicalandeconomicoutcomesassociatedwithadjuvantedversushighdosetrivalentinfluenzavaccineamongadultsaged65yearsintheusduringthe201920influenzaseasonaretrospectivecohortanalysis
AT postmamaartenj comparingtheclinicalandeconomicoutcomesassociatedwithadjuvantedversushighdosetrivalentinfluenzavaccineamongadultsaged65yearsintheusduringthe201920influenzaseasonaretrospectivecohortanalysis